# Empagliflozin Add on to Linagliptin Study in Japanese Patient With Type 2 Diabetes Mellitus

> **NCT02453555** · PHASE3 · COMPLETED · sponsor: **Boehringer Ingelheim** · enrollment: 275 (actual)

## Conditions studied

- Diabetes Mellitus, Type 2

## Interventions

- **DRUG:** Linagliptin
- **DRUG:** Empagliflozin placebo + linagliptin placebo low dose
- **DRUG:** Empagliflozin + linagliptin low dose
- **DRUG:** Linagliptin placebo
- **DRUG:** Empagliflozin + linagliptin high dose
- **DRUG:** Empa + lina highdose placebo

## Key facts

- **NCT ID:** NCT02453555
- **Lead sponsor:** Boehringer Ingelheim
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-05-14
- **Primary completion:** 2016-08-26
- **Final completion:** 2017-03-27
- **Target enrollment:** 275 (ACTUAL)
- **Last updated:** 2019-02-15

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02453555

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02453555, "Empagliflozin Add on to Linagliptin Study in Japanese Patient With Type 2 Diabetes Mellitus". Retrieved via AI Analytics 2026-06-05 from https://api.ai-analytics.org/clinical/NCT02453555. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*